Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estroprogestins with Interferon-Beta 1a in RRMS
NCT00151801Phase 2Unknown
- Sponsor
- Sant'Andrea Hospital
- Start
- May 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of desogestrel and ethinyl estradiol in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Sant'Andrea Hospital. Primary endpoints: Safety assessment including adverse events, physical examination and laboratory parameters at 24 months, Relapse rate at 24 months and 2 more. Status: unknown.
02
Drugs
desogestrelethinyl estradiol
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00151801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151801.